LAS VEGAS, Aug. 27, 2009 (GLOBE NEWSWIRE) -- A report addressing one company's research using human bone marrow stem cells has been released. The report will explore the efforts of BrainStorm (OTCBB: BCLI) and is of interest to investors of leading stem cell equities Geron (Nasdaq:GERN), Osiris Therapeutics (Nasdaq:OSIR), Aastrom Biosciences (Nasdaq:ASTM) and StemCells (Nasdaq:STEM).
View the report at: www.SmallCapSentinel.com/bcli
From the report: BrainStorm (OTCBB:BCLI) is a leading developer of stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. The Company is focused on developing NTF cells from the patient's own bone marrow in order to treat, Parkinson, ALS, and Spinal Cord Injury.
The adult stem cells are used to create healthy NTF cells which produce and secrete neurotrophic factors, which are essential for the survival and outgrowth of neurons, and may become beneficial in neurodegenerative diseases. Patients treated with the Company's NurOwn(tm) therapeutic cells are expected to enjoy a rapid recovery and much enhanced quality of life. BrainStorm's therapy has the potential to cure underlying pathology, rather than simply treat symptoms. BrainStorm's management and scientific teams are passionately devoted to the Company's mission: regenerating the mind... in their lifetime.
Please register to receive more information on BCLI and other emerging public companies at:
www.SmallCapSentinel.com/register
Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SmallCapSentinel.com is property of Integrity Media Inc. (IMI). IMI provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience. The subject companies haven't always approved the statements made in this report. This report is neither a solicitation to buy nor offer to sell securities and is for information purposes only and shouldn't be used as basis for investment decisions. IMI isn't an investment advisor, analyst or licensed broker dealer and this report isn't investment advice. In exchange for advertising and investor relations services related to BCLI over a twelve-month period, IMI is the beneficial owner of 625,000 shares of BCLI held by Emerging Markets Consulting (EMC), an investor relations consultant to BCLI which has been paid 1,250,000 total shares for twelve months of investor relations and related advertising. Paid reports constitute a conflict of interest as to IMI's ability to remain objective in communication regarding subject companies.
CONTACT: Integrity Media Inc.
Kurt Divich
702-396-1000
